ArticleFrontiers in medicine2022
Novel oxazolidinones harbor potent
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Contezolid in the Treatment of Multidrug-Resistant Tuberculous Meningitis: A Case Report.Clinical case reports · 2026Article
- Safety and Effectiveness of Contezolid versus Linezolid in Drug-Resistant Tuberculosis: A 12-Month Retrospective Study from China.Infection and drug resistance · 2026Article
- The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review.Infectious diseases and therapy · 2026Review
- Concentration of contezolid in cerebrospinal fluid and serum in a patient with renal allograft tuberculosis and tuberculous meningoencephalitis.BMC infectious diseases · 2025Article
- Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones AgainstPathogens (Basel, Switzerland) · 2025Article
- Treatment of Tuberculous Meningitis With Contezolid in a Patient With Complex Comorbidities: A Case Report and Literature Review.Case reports in infectious diseases · 2025Article
- Contezolid Harbored Equivalent Efficacy to Linezolid in Tuberculosis Treatment in a Prospective and Randomized Early Bactericidal Activity Study.Infection and drug resistance · 2025Article
- ThePeerJ · 2025Review
- Successful Treatment of Severe Tuberculosis With Contezolid Add-On Regimen in a Patient Complicated With Acute Thrombocytopenia: A Case Report.Clinical case reports · 2024Article
- New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?Pharmaceutics · 2024Review
- The Therapeutic Effect of Contezolid in Complex Intra-Abdominal Infections.Infection and drug resistance · 2024Article
- Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.Scientific reports · 2023Article
- Antibiotics in the clinical pipeline as of December 2022.The Journal of antibiotics · 2023Review
- Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients.Infection and drug resistance · 2023Article
- Tuberculosis patients with special clinical conditions treated with contezolid: three case reports and a literature review.Frontiers in medicine · 2023Article
- Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid-a typical case report and literature review.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the Materials and methods: The minimum inhibitory concentrations (MICs) of linezolid, tedizolid, sutezolid, delpazolid, and contezolid against 16 mycobacterial reference strains and 69 Results: Tedizolid exhibited the strongest inhibitory activities against the reference strains of both rapidly growing mycobacteria (RGM) and slowly growing mycobacteria (SGM), among the tested oxazolidinones. In contrast, sutezolid only manifested potent activity against reference strains of SGM. Linezolid, delpazolid, and contezolid were less active against the non-tuberculous mycobacterial references. For the Mtb clinical isolates, the antimicrobial action was ranked as: sutezolid > tedizolid > contezolid and linezolid > delpazolid, whereas no difference between drug-sensitive and multiple drug-resistant isolates was observed. Notably, contezolid demonstrated obviously superior intracellular antimicrobial activity than linezolid. Few strains harbored mutations in Conclusion: Different oxazolidinones can have discrepant antimicrobial activity against different mycobacterial species, or have different manifestations out of cell or in cell. Understanding these differences would be helpful in choosing the appropriate drug in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.